All In Biotech

Drug Trial Radar · NCT04971447

Extracellular Vesicles and Endothelial Function in Transgender Subjects

Effects of Plasma Extracellular Vesicles on Endothelial Function in Transgender Subjects

Last checked: Nov 20, 2026Latest source record: Jul 25, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

136

Planned (sponsor's estimate)

Start

Aug 2022

Primary completion

Sep 2023

Study completion Jan 2024

Sponsor

Lead sponsor
Central Hospital, Nancy, FranceAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 21, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 49 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Cardiovascular diseases are the leading cause of mortality. In women, the prevalence of cardiovascular diseases is lower and the presentation of coronary events often atypical. The lack of evidence is related in part to the methodology of studies not considering sex as an essential biological variable. Hormonal treatment is prescribed in transgender subjects to promote the development of sexual characteristics of the desired sex. Early cardiovascular effects of hormonal treatment have been reported in transgender men, while long-term mortality is higher in transgender women. The aim of this project is to study the effects of gender affirming hormonal treatment on arterial stiffness in young transgender subjects followed at the University Hospital of Nancy.

Conditions

  • Transgenderism

Interventions

  • gender affirming hormonal treatment in transgender menDrug

    testosterone enanthate

  • gender affirming hormonal treatment in transgender womenDrug

    GnRH agonists + estrogen

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. pulse wave velocityTime frame: 24 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.